

FOR OFFICIAL USE ONLY

187213

ACCESS DB #
PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Rohat (Rah) Shiao Examiner #: 79521 Date: 9/26/06
Art Unit: 1626 Phone Number: 2-0707 Serial Number: 10500317
Location (Bldg/Room#): REIT (Mailbox #): 5410 Results Format Preferred (circle): PAPER DISK

SCIP

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Drug delivery for curing asthma
Inventors (please provide full names): Ishihara et al


Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

2. Search cpd 2 (see claim 45)



2. Search cpd 2 of
claim 5)

* L, L2 is alkyls

* R is sub

* X is a bond or

O, N

* Ar2 is aryl

STAFF USE ONLY

Searcher: garSearcher Phone #: 22504

Searcher Location: _____

Date Searcher Picked Up: 5/22/06Date Completed: 5/22/06Searcher Prep & Review Time: 15Online Time: 425

Type of Search

____ NA Sequence (#)

____ AA Sequence (#)

____ ☒ Structure (#)

____ Bibliographic

____ Litigation

____ Fulltext

____ Other

Vendors and cost where applicable

☒ STN _____ Dialog

____ Questel/Orbit _____ Lexis/Nexis


____ Westlaw _____ WWW/Internet

____ In-house sequence systems

____ Commercial _____ Oligomer _____ Score/Length

____ Interference _____ SPDI _____ Encode/Transl

____ Other (specify)



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 187213

TO: Rei-Tsang Shiao
Location: 5a10 / 5c18
Monday, May 22, 2006
Art Unit: 1626
Phone: 571-272-0707
Serial Number: 10 / 500217

From: Jan Delaval
Location: Biotech-Chem Library
Remsen 1a51
Phone: 571-272-2504

jan.delaval@uspto.gov

Search Notes



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact:*

Mary Hale, Information Branch Supervisor
22507, Remsen 1d86

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 – Circ. Desk



=> fil reg

FILE 'REGISTRY' ENTERED AT 10:55:35 ON 22 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7
DICTIONARY FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>


=> d l38 ide can tot

L38 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
RN 773845-97-9 REGISTRY
ED Entered STN: 02 Nov 2004
CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-
1,3-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H26 Cl N3 O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L38 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
RN 562040-93-1 REGISTRY
ED Entered STN: 06 Aug 2003
CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-
1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
MF C22 H26 Cl N3 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (773845-97-9)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:100419

REFERENCE 2: 139:111692

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 10:55:42 ON 22 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:55:42 ON 22 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr tot 142

L42 ANSWER 1 OF 2 USPATFULL on STN
AN 2006:74720 USPATFULL
TI Preventives/remedies for urinary disturbance
IN Ishihara, Yuji, Itami-shi, JAPAN
Ishichi, Yuji, Sakai-shi, JAPAN
Doi, Takayuki, Osaka-shi, JAPAN
Nagabukuro, Hiroshi, Osaka-shi, JAPAN
Kanzaki, Naoyuki, Ibaraki-shi, JAPAN
Ikeuchi, Motoki, Nishinomiya-shi, JAPAN
PI US 2006063769 A1 20060323
AI US 2002-500217 A1 20021226 (10)
WO 2002-JP13653 20021226
20040625 PCT 371 date
PRAI JP 2001-2004402064 20011228

jan delaval - 22 may 2006

JP 2002-72027 20020315
 DT Utility
 FS APPLICATION
 LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800,
 WASHINGTON, DC, 20006-1021, US
 CLMN Number of Claims: 6
 ECL Exemplary Claim: 1-43
 DRWN No Drawings
 LN.CNT 13923
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Preventives/remedies for voiding disturbance containing a compound
 having both of an acetylcholinesterase inhibitory action and an $\alpha 1$
 antagonistic action which exhibits an excellent effect of improving the
 urinary function of the bladder (i.e., effects of improving urine flow
 rate and voiding efficiency) without affecting the urinary pressure or
 the blood pressure.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 562040-93-1P

(heterocyclic compds. having acetylcholine esterase inhibitory and
 $\alpha 1$ antagonistic effects as preventives/remedies for urinary
 disturbance)

RN 562040-93-1 USPATFULL

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-
 1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L42 ANSWER 2 OF 2 USPATFULL on STN
 AN 2005:227510 USPATFULL
 TI Preventives/remedies for urinary disturbance
 IN Ishihara, Yuji, Itami-shi, JAPAN
 Ishichi, Yuji, Sakai-shi, JAPAN
 Doi, Takayuki, Osaka-shi, JAPAN
 Nagabukuro, Hiroshi, Osaka-shi, JAPAN
 Kanzaki, Naoyuki, Ibaraki-shi, JAPAN
 Ikeuchi, Motoki, Nishinomiya-shi, JAPAN
 PI US 2005197362 A1 20050908
 AI US 2004-935646 A1 20040908 (10)
 RLI Division of Ser. No. US 500217, PENDING A 371 of International Ser. No.
 WO 2002-JP13653, filed on 26 Dec 2002
 PRAI JP 2001-402064 20011228
 JP 2002-72027 20020315
 DT Utility
 FS APPLICATION
 LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800,

WASHINGTON, DC, 20006-1021, US

CLMN Number of Claims: 43

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 13787

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an $\alpha 1$ antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 562040-93-1P

(heterocyclic compds. having acetylcholine esterase inhibitory and $\alpha 1$ antagonistic effects as preventives/remedies for urinary disturbance)

RN 562040-93-1 USPATFULL

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 10:55:52 ON 22 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 May 2006 VOL 144 ISS 22

FILE LAST UPDATED: 19 May 2006 (20060519/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr tot 141 retable

L41 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:14256 HCAPLUS

DN 142:100419

TI Preventive/remedy for urinary disturbance

IN Doi, Takayuki; Nagabukuro, Hiroshi

PA Takeda Pharmaceutical Company Limited, Japan

SO PCT Int. Appl., 258 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2005000354	A1	20050106	WO 2004-JP9486	20040629	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2531019	AA	20050106	CA 2004-2531019	20040629	
	JP 2005035996	A2	20050210	JP 2004-192142	20040629	
	EP 1640021	A1	20060329	EP 2004-746955	20040629	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK		

PRAI JP 2003-188761 A 20030630

WO 2004-JP9486 W 20040629

AB It is intended to provide a preventive/remedy for urinary disturbance containing a compound, which shows an acetylcholine esterase inhibitory activity

but substantially has no butyrylcholine esterase inhibitory activity, showing no side effect and being safe and efficacious without inhibiting the urine collection function; a preventive/remedy for dry mouth induced by the administration of a remedy for urinary disturbance and a preventive/remedy for hyperactive bladder not accompanied by dry mouth; and a method of screening a substance preventing/treating urinary disturbance without inhibiting the urine collection function characterized by comprising measuring and comparing the acetylcholine esterase inhibitory activity and the butyrylcholine esterase inhibitory activity of a test compound A selective acetylcholine esterase inhibitory activity of 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (I) was in vitro tested. Also, I inhibited oxybutynin-induced hyposalivation in rats.


IT 562040-93-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preventive/remedy for urinary disturbance containing selective acetylcholine esterase inhibitors)

RN 562040-93-1 HCAPLUS

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
=====	=====	=====	=====	=====	=====
Anon				WO 00/18391 A1	HCAPLUS
Anon				EP 1118322 A1	HCAPLUS
Anon				JP 2001-335576 A	HCAPLUS
Anon				US 2002/0177593 A1	HCAPLUS
Anon				JP 2003-192593 A	HCAPLUS
Anon				JP 2003-201237 A	HCAPLUS
Anon				JP 2003-335701 A	HCAPLUS
Anon				EP 607864 A1	HCAPLUS
Takeda Chemical Industr	1995			JP 07-206854 A	HCAPLUS
Takeda Chemical Industr	2000			JP 2000-169373 A	HCAPLUS
Takeda Chemical Industr	2003			WO 03/057254 A1	HCAPLUS

L41 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:551407 HCAPLUS

DN 139:111692

TI Preventives/remedies for urinary disturbance

IN Ishihara, Yuji; Ishichi, Yuji; Doi, Takayuki
; Nagabukuro, Hiroshi; Kanzaki, Naoyuki; Ikeuchi,
Motoki

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 520 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	-----	-----	-----	-----
PI	WO 2003057254	A1	20030717	WO 2002-JP13653	20021226 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

CA 2471760 AA 20030717 CA 2002-2471760 20021226 <--
 AU 2002367425 A1 20030724 AU 2002-367425 20021226 <--
 JP 2003335701 A2 20031128 JP 2002-377956 20021226 <--
 EP 1466625 A1 20041013 EP 2002-790890 20021226 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 BR 2002015389 A 20041026 BR 2002-15389 20021226 <--
 CN 1589153 A 20050302 CN 2002-828398 20021226 <--
 US 2006063769 A1 20060323 US 2004-500217 20040624 <--
 ZA 2004005123 A 20050628 ZA 2004-5123 20040628 <--
 US 2005197362 A1 20050908 US 2004-935646 20040908 <--
 JP 2006104208 A2 20060420 JP 2005-330218 20051115 <--
 PRAI JP 2001-402064 A 20011228 <--
 JP 2002-72027 A 20020315 <--
 JP 2004-402064 A 20011228
 JP 2003-557611 A3 20021226
 WO 2002-JP13653 W 20021226 <--
 US 2004-500217 A3 20040624 <--
 OS MARPAT 139:111692
 AB Preventives/remedies for urinary disturbance containing a compound having both
 of an acetylcholine esterase inhibitory effect and an $\alpha 1$
 antagonistic effect which exhibits an excellent effect of improving the
 urinary function of the bladder (i.e., effects of improving urine flow
 rate and urinary efficiency) without affecting the urinary pressure or the
 blood pressure.
 IT **562040-93-1P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (heterocyclic compds. having acetylcholine esterase inhibitory and
 $\alpha 1$ antagonistic effects as preventives/remedies for urinary
 disturbance)
 RN 562040-93-1 HCAPLUS
 CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-
 1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Eisai Co Ltd	2000			WO 0051985 A1	HCAPLUS
Eisai Co Ltd	2000			JP 2000319258 A	HCAPLUS
Eisai Co Ltd	2001			WO 0116105 A1	HCAPLUS
Eisai Co Ltd	2001			JP 2001139547 A	HCAPLUS
Kissei Pharmaceutical C	1995			JP 07-330725 A1	HCAPLUS

Kissei Pharmaceutical C	1995		JP 07-330726 A1	HCAPLUS
Kissei Pharmaceutical C	1997		JP 09-143182 A1	HCAPLUS
Kyowa Hakko Kogyo Co Lt	1999		AU 9894620 A1	HCAPLUS
Kyowa Hakko Kogyo Co Lt	1999		WO 9919326 A1	HCAPLUS
Ortho-McNeil Pharmaceut	1999		JP 2002503724 A	
Ortho-McNeil Pharmaceut	1999		WO 9942448 A1	HCAPLUS
Sankyo Co Ltd	1993		JP 06-271569 A	HCAPLUS
Sankyo Co Ltd	1993		JP 06-41070 A	HCAPLUS
Sankyo Co Ltd	1993		EP 562832 A1	HCAPLUS
Takeda Chemical Industr	1994		JP 07-206854 A	HCAPLUS
Takeda Chemical Industr	1994		EP 607864 A1	HCAPLUS
Takeda Chemical Industr	2000		WO 00018391 A1	HCAPLUS
Takeda Chemical Industr	2000		EP 1118322 A1	HCAPLUS
Takeda Chemical Industr	2000		JP 2000169373 A	HCAPLUS
Takeda Chemical Industr	2000		JP 2001335576 A	HCAPLUS

=> => fil reg

FILE 'REGISTRY' ENTERED AT 11:04:23 ON 22 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7

DICTIONARY FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d sta que 145

L43 STR



VAR G1=2/1
 VAR G2=CY/18/20
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE
 L45 73 SEA FILE=REGISTRY SSS FUL L43

100.0% PROCESSED 2212 ITERATIONS
 SEARCH TIME: 00.00.01

73 ANSWERS

=> d his

(FILE 'HOME' ENTERED AT 10:43:29 ON 22 MAY 2006)
 DEL HIS

FILE 'HCAPLUS' ENTERED AT 10:44:43 ON 22 MAY 2006

SET COST OFF
 L1 1 S (US20060063769 OR US20050197362)/PN OR (US2004-500217# OR US2
 E ISHIHARA/AU
 E ISHIHARA Y/AU
 L2 94 S E3
 E ISHIHARA YU/AU
 L3 84 S E3,E6
 E YUJI/AU
 L4 6 S E3
 E ISHICHI/AU
 L5 19 S E4,E8
 E DOI/AU
 L6 1 S E3
 E DOI T/AU
 L7 366 S E3,E4,E30
 E TAKAYUKI/AU
 L8 2 S E3
 E NAGABUKURO/AU
 L9 17 S E6,E7
 E HIROSHI/AU
 L10 14 S E3
 E HIROSHI N/AU
 L11 4 S E11
 E KANXAKI/AU

jan delaval - 22 may 2006

L12 E KANZAKI/AU
 1 S E3
 E KANZAKI N/AU
 L13 85 S E3,E4,E7
 E NAOYUKI/AU
 E IKEUCHI/AU
 E IKEUCHI M/AU
 L14 35 S E3
 E IKEUCHI MO/AU
 L15 19 S E5,E9
 E MOTOKI/AU
 L16 1 S E88
 E ISHIHARA N/AU
 L17 14 S E6
 E YUJI N/AU
 L18 17 S E6
 E ISHICHI N/AU
 E YUJI N/AU
 L19 17 S E6
 E DOI N/AU
 L20 13 S E6
 E TAKAYUKI N/AU
 E NAGABUKURO N/AU
 E HIROSHI N/AU
 L21 4 S E11
 E KANZAKI N/AU
 L22 4 S E4
 E NAOYUKI N/AU
 E IKEUCHI N/AU
 L23 7 S E4
 E MOTOKI N/AU
 L24 1 S E4
 L25 14848 S TAKEDA?/PA,CS
 L26 1 S L1 AND L2-L24
 L27 1 S L1 AND L25
 L28 1 S L1,L26,L27

FILE 'REGISTRY' ENTERED AT 10:51:33 ON 22 MAY 2006

FILE 'HCAPLUS' ENTERED AT 10:51:40 ON 22 MAY 2006

L29 TRA L28 1- RN : 641 TERMS

FILE 'REGISTRY' ENTERED AT 10:51:41 ON 22 MAY 2006

L30 641 SEA L29
 L31 34 S L30 AND NCNC2-C6/ES AND 46.150.18/RID AND 3/NR
 L32 12 S L31 AND 3/N AND 2/O AND CL/ELS
 L33 1 S L32 AND 1/NC
 L34 5 S L31 AND 22/C
 L35 1 S L34 AND C22H26CLN3O2
 L36 1 S 773845-97-9
 L37 1 S 773845-97-9/CRN
 L38 2 S L36,L37

FILE 'HCAOLD' ENTERED AT 10:54:55 ON 22 MAY 2006

L39 0 S L38

FILE 'HCAPLUS' ENTERED AT 10:54:56 ON 22 MAY 2006

L40 2 S L38
 L41 2 S L40 AND L1-L28

L42 FILE 'USPATFULL, USPAT2' ENTERED AT 10:55:16 ON 22 MAY 2006
2 S L38

FILE 'REGISTRY' ENTERED AT 10:55:35 ON 22 MAY 2006

FILE 'USPATFULL, USPAT2' ENTERED AT 10:55:42 ON 22 MAY 2006

FILE 'HCAPLUS' ENTERED AT 10:55:52 ON 22 MAY 2006

FILE 'REGISTRY' ENTERED AT 10:56:26 ON 22 MAY 2006

L43 STR
L44 2 S L43
L45 73 S L43 FUL
SAV L45 TEMP SHIAO500/A
L46 71 S L45 NOT L38
L47 29 S L46 NOT L30
L48 22 S L47 AND NCNC2-C6/ES
L49 7 S L47 NOT L48
L50 42 S L46 AND L30
L51 71 S L46-L50
SAV TEMP L51 SHIAO500A/A

L52 FILE 'HCAOLD' ENTERED AT 11:03:30 ON 22 MAY 2006
0 S L51

FILE 'HCAPLUS' ENTERED AT 11:03:33 ON 22 MAY 2006
L53 3 S L51
L54 2 S L53 AND L1-L25
L55 1 S L53 NOT L54

FILE 'USPATFULL, USPAT2' ENTERED AT 11:04:13 ON 22 MAY 2006
L56 2 S L51

FILE 'REGISTRY' ENTERED AT 11:04:23 ON 22 MAY 2006

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 11:04:31 ON 22 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:04:31 ON 22 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l56 bib abs hitrn fhitrstr tot

L56 ANSWER 1 OF 2 USPATFULL on STN
AN 2006:74720 USPATFULL
TI Preventives/remedies for urinary disturbance
IN Ishihara, Yuji, Itami-shi, JAPAN
Ishichi, Yuji, Sakai-shi, JAPAN
Doi, Takayuki, Osaka-shi, JAPAN
Nagabukuro, Hiroshi, Osaka-shi, JAPAN
Kanzaki, Naoyuki, Ibaraki-shi, JAPAN
Ikeuchi, Motoki, Nishinomiya-shi, JAPAN
PI US 2006063769 A1 20060323
AI US 2002-500217 A1 20021226 (10)
WO 2002-JP13653 20021226
20040625 PCT 371 date
PRAI JP 2001-2004402064 20011228
JP 2002-72027 20020315
DT Utility

FS APPLICATION
 LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800,
 WASHINGTON, DC, 20006-1021, US
 CLMN Number of Claims: 6
 ECL Exemplary Claim: 1-43
 DRWN No Drawings
 LN.CNT 13923

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an $\alpha 1$ antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 562040-40-8P 562040-41-9P 562040-82-8P
 562040-83-9P 562040-85-1P 562040-86-2P
 562040-88-4P 562040-89-5P 562040-90-8P
 562040-91-9P 562040-92-0P 562041-73-0P
 562041-74-1P 562041-75-2P 562041-76-3P
 562042-03-9P 562042-07-3P 562042-11-9P
 562042-14-2P 562043-03-2P 562043-18-9P
 562043-19-0P 562043-20-3P 562043-21-4P
 562043-22-5P 562043-37-2P 562043-40-7P
 562043-41-8P 562043-42-9P

(heterocyclic compds. having acetylcholine esterase inhibitory and $\alpha 1$ antagonistic effects as preventives/remedies for urinary disturbance)


IT 562037-96-1P 562037-97-2P 562037-98-3P
 562038-87-3P 562038-92-0P 562038-95-3P
 562039-36-5P 562039-37-6P 562039-38-7P
 562039-39-8P 562039-51-4P 562039-52-5P
 562039-53-6P

(heterocyclic compds. having acetylcholine esterase inhibitory and $\alpha 1$ antagonistic effects as preventives/remedies for urinary disturbance)

IT 562040-40-8P
 (heterocyclic compds. having acetylcholine esterase inhibitory and $\alpha 1$ antagonistic effects as preventives/remedies for urinary disturbance)

RN 562040-40-8 USPATFULL

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L56 ANSWER 2 OF 2 USPATFULL on STN

jan delaval - 22 may 2006

AN 2005:227510 USPATFULL
 TI Preventives/remedies for urinary disturbance
 IN Ishihara, Yuji, Itami-shi, JAPAN
 Ishichi, Yuji, Sakai-shi, JAPAN
 Doi, Takayuki, Osaka-shi, JAPAN
 Nagabukuro, Hiroshi, Osaka-shi, JAPAN
 Kanzaki, Naoyuki, Ibaraki-shi, JAPAN
 Ikeuchi, Motoki, Nishinomiya-shi, JAPAN
 PI US 2005197362 A1 20050908
 AI US 2004-935646 A1 20040908 (10)
 RLI Division of Ser. No. US 500217, PENDING A 371 of International Ser. No.
 WO 2002-JP13653, filed on 26 Dec 2002
 PRAI JP 2001-402064 20011228
 JP 2002-72027 20020315
 DT Utility
 FS APPLICATION
 LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800,
 WASHINGTON, DC, 20006-1021, US
 CLMN Number of Claims: 43
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 13787

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an $\alpha 1$ antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 562040-40-8P 562040-41-9P 562040-82-8P
 562040-83-9P 562040-85-1P 562040-86-2P
 562040-88-4P 562040-89-5P 562040-90-8P
 562040-91-9P 562040-92-0P 562041-73-0P
 562041-74-1P 562041-75-2P 562041-76-3P
 562042-03-9P 562042-07-3P 562042-11-9P
 562042-14-2P 562043-03-2P 562043-18-9P
 562043-19-0P 562043-20-3P 562043-21-4P
 562043-22-5P 562043-37-2P 562043-40-7P
 562043-41-8P 562043-42-9P
 (heterocyclic compds. having acetylcholine esterase inhibitory and $\alpha 1$ antagonistic effects as preventives/remedies for urinary disturbance)

IT 562037-96-1P 562037-97-2P 562037-98-3P
 562038-87-3P 562038-92-0P 562038-95-3P
 562039-36-5P 562039-37-6P 562039-38-7P
 562039-39-8P 562039-51-4P 562039-52-5P
 562039-53-6P
 (heterocyclic compds. having acetylcholine esterase inhibitory and $\alpha 1$ antagonistic effects as preventives/remedies for urinary disturbance)

IT 562040-40-8P
 (heterocyclic compds. having acetylcholine esterase inhibitory and $\alpha 1$ antagonistic effects as preventives/remedies for urinary disturbance)

RN 562040-40-8 USPATFULL

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 11:04:44 ON 22 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 May 2006 VOL 144 ISS 22

FILE LAST UPDATED: 19 May 2006 (20060519/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l54 bib abs hitrn fhitrstr retable tot

L54 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:14256 HCAPLUS

DN 142:100419

TI Preventive/remedy for urinary disturbance

IN Doi, Takayuki; Nagabukuro, Hiroshi

PA Takeda Pharmaceutical Company Limited, Japan

SO PCT Int. Appl., 258 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000354	A1	20050106	WO 2004-JP9486	20040629
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

CA 2531019 AA 20050106 CA 2004-2531019 20040629
 JP 2005035996 A2 20050210 JP 2004-192142 20040629
 EP 1640021 A1 20060329 EP 2004-746955 20040629

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI JP 2003-188761 A 20030630
 WO 2004-JP9486 W 20040629

AB It is intended to provide a preventive/remedy for urinary disturbance
 containing a compound, which shows an acetylcholine esterase inhibitory
 activity

but substantially has no butyrylcholine esterase inhibitory activity,
 showing no side effect and being safe and efficacious without inhibiting
 the urine collection function; a preventive/remedy for dry mouth induced
 by the administration of a remedy for urinary disturbance and a
 preventive/remedy for hyperactive bladder not accompanied by dry mouth;
 and a method of screening a substance preventing/treating urinary
 disturbance without inhibiting the urine collection function characterized
 by comprising measuring and comparing the acetylcholine esterase
 inhibitory activity and the butyrylcholine esterase inhibitory activity of
 a test compound A selective acetylcholine esterase inhibitory activity of
 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-
 tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (I) was in vitro tested.
 Also, I inhibited oxybutynin-induced hyposalivation in rats.

IT 562040-40-8 562040-41-9 562040-92-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(preventive/remedy for urinary disturbance containing selective
 acetylcholine esterase inhibitors)


IT 562040-40-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(preventive/remedy for urinary disturbance containing selective
 acetylcholine esterase inhibitors)

RN 562040-40-8 HCAPLUS

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-
 oxopentyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
----------------------------	---------------	--------------	-------------	--------------------------	--------------------

Anon				WO 00/18391 A1	HCAPLUS
Anon				EP 1118322 A1	HCAPLUS
Anon				JP 2001-335576 A	HCAPLUS
Anon				US 2002/0177593 A1	HCAPLUS
Anon				JP 2003-192593 A	HCAPLUS
Anon				JP 2003-201237 A	HCAPLUS
Anon				JP 2003-335701 A	HCAPLUS
Anon				EP 607864 A1	HCAPLUS
Takeda Chemical Industr	1995			JP 07-206854 A	HCAPLUS
Takeda Chemical Industr	2000			JP 2000-169373 A	HCAPLUS
Takeda Chemical Industr	2003			WO 03/057254 A1	HCAPLUS

154 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:551407 HCAPLUS

DN 139:111692

TI Preventives/remedies for urinary disturbance

IN Ishihara, Yuji; Ishichi, Yuji; Doi, Takayuki
; Nagabukuro, Hiroshi; Kanzaki, Naoyuki; Ikeuchi,
Motoki

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 520 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057254	A1	20030717	WO 2002-JP13653	20021226 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2471760	AA	20030717	CA 2002-2471760	20021226 <--
	AU 2002367425	A1	20030724	AU 2002-367425	20021226 <--
	JP 2003335701	A2	20031128	JP 2002-377956	20021226 <--
	EP 1466625	A1	20041013	EP 2002-790890	20021226 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002015389	A	20041026	BR 2002-15389	20021226 <--
	CN 1589153	A	20050302	CN 2002-828398	20021226 <--
	US 2006063769	A1	20060323	US 2004-500217	20040624 <--
	ZA 2004005123	A	20050628	ZA 2004-5123	20040628 <--
	US 2005197362	A1	20050908	US 2004-935646	20040908 <--
	JP 2006104208	A2	20060420	JP 2005-330218	20051115 <--
PRAI	JP 2001-402064	A	20011228	<--	
	JP 2002-72027	A	20020315	<--	
	JP 2004-402064	A	20011228		
	JP 2003-557611	A3	20021226		
	WO 2002-JP13653	W	20021226	<--	
	US 2004-500217	A3	20040624	<--	
OS	MARPAT 139:111692				
AB	Preventives/remedies for urinary disturbance containing a compound having both of an acetylcholine esterase inhibitory effect and an $\alpha 1$				

antagonistic effect which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and urinary efficiency) without affecting the urinary pressure or the blood pressure.

IT 562040-40-8P 562040-41-9P 562040-82-8P
562040-83-9P 562040-85-1P 562040-86-2P
562040-88-4P 562040-89-5P 562040-90-8P
562040-91-9P 562040-92-0P 562041-73-0P
562041-74-1P 562041-75-2P 562041-76-3P
562042-03-9P 562042-07-3P 562042-11-9P
562042-14-2P 562043-03-2P 562043-18-9P
562043-19-0P 562043-20-3P 562043-21-4P
562043-22-5P 562043-37-2P 562043-40-7P
562043-41-8P 562043-42-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(heterocyclic compds. having acetylcholine esterase inhibitory and $\alpha 1$ antagonistic effects as preventives/remedies for urinary disturbance)

IT 562037-96-1P 562037-97-2P 562037-98-3P
562038-87-3P 562038-92-0P 562038-95-3P
562039-36-5P 562039-37-6P 562039-38-7P
562039-39-8P 562039-51-4P 562039-52-5P
562039-53-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(heterocyclic compds. having acetylcholine esterase inhibitory and $\alpha 1$ antagonistic effects as preventives/remedies for urinary disturbance)


IT 562040-40-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(heterocyclic compds. having acetylcholine esterase inhibitory and $\alpha 1$ antagonistic effects as preventives/remedies for urinary disturbance)

RN 562040-40-8 HCAPLUS

CN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Eisai Co Ltd	2000			WO 0051985 A1	HCAPLUS
Eisai Co Ltd	2000			JP 2000319258 A	HCAPLUS

Eisai Co Ltd	2001			WO 0116105 A1	HCAPLUS
Eisai Co Ltd	2001			JP 2001139547 A	HCAPLUS
Kissei Pharmaceutical C	1995			JP 07-330725 A1	HCAPLUS
Kissei Pharmaceutical C	1995			JP 07-330726 A1	HCAPLUS
Kissei Pharmaceutical C	1997			JP 09-143182 A1	HCAPLUS
Kyowa Hakko Kogyo Co Lt	1999			AU 9894620 A1	HCAPLUS
Kyowa Hakko Kogyo Co Lt	1999			WO 9919326 A1	HCAPLUS
Ortho-McNeil Pharmaceut	1999			JP 2002503724 A	
Ortho-McNeil Pharmaceut	1999			WO 9942448 A1	HCAPLUS
Sankyo Co Ltd	1993			JP 06-271569 A	HCAPLUS
Sankyo Co Ltd	1993			JP 06-41070 A	HCAPLUS
Sankyo Co Ltd	1993			EP 562832 A1	HCAPLUS
Takeda Chemical Industr	1994			JP 07-206854 A	HCAPLUS
Takeda Chemical Industr	1994			EP 607864 A1	HCAPLUS
Takeda Chemical Industr	2000			WO 00018391 A1	HCAPLUS
Takeda Chemical Industr	2000			EP 1118322 A1	HCAPLUS
Takeda Chemical Industr	2000			JP 2000169373 A	HCAPLUS
Takeda Chemical Industr	2000			JP 2001335576 A	HCAPLUS

=> d 155 bib abs hitstr retable

L55 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 1956:44539 HCAPLUS
 DN 50:44539
 OREF 50:8606g-i,8607a-i,8608a-c
 TI Synthesis of compounds related to adrenaline
 AU Vaughan, James R., Jr.; Blodinger, Jack
 CS American Cyanamid, Stamford, CT
 SO Journal of the American Chemical Society (1955), 77, 5757-60
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA Unavailable
 OS CASREACT 50:44539
 AB PhCH₂NHMe (21.0 g.) in 100 cc. Et₂O added to 22.6 g. 3,4-(MeO)₂C₆H₃COCH₂Br in 1 l. dry Et₂O, the mixture allowed to stand overnight, the PhCH₂NHMe.HCl (16.8 g.) filtered off, the filtrate washed with two 300-cc. portions H₂O, dried, and saturated with dry HCl, and the gummy solid precipitate recrystd. from 200 cc. EtAc yielded 12.5 g. colorless needles which recrystd. twice from EtAc by Soxhlet extraction gave 11.6 g. 3,4-(MeO)₂C₆H₃COCH₂NMeCH₂Ph (I), m. 184-6° (all m.ps. are corrected). I (3.35 g.) in 30 cc. EtOH hydrogenated 10 hrs. at room temperature and 50 lb. pressure over 0.2-0.3 g. 10% Pd-C, the mixture warmed, filtered hot, and cooled, and the colorless crystalline deposit (0.60 g.) recrystd. twice from 20-cc. portions EtOH gave 3,4-(MeO)₂C₆H₃COCH₂NHMe, m. 217-20° (decomposition) with softening above 211°; the original filtrate diluted with 10 cc. Et₂O and the resulting precipitate (1.15 g.) recrystd. twice from 1:1 EtOH-Et₂O gave 3,4-(MeO)₂C₆H₃CH(OH)CH₂NHMe, m. 114-15°. Benzimidazolone (36 g.) and 47 g. AcCl in 183 g. CS₂ treated with good stirring during 15 min. with 160 g. anhydrous AlCl₃, the mixture heated on the steam bath 2 hrs. with stirring, the resulting brown tarry mass poured onto 250 g. cracked ice and treated dropwise with 15 cc. concentrated HCl, the resulting brown solid washed with H₂O and recrystd. with Darco from 1.5 l. 95% EtOH, and the product (30 g.) recrystd. 4 times with Darco from 95% EtOH yielded 15 g. 5-acetyl-2-benzimidazolinone (II), m. 294-5°. 3,4-(H₂N)₂C₆H₃Ac (2.4

g.) in 50 cc. dilute HCl cooled while being bubbled 10-15 min. with COCl₂, and the resulting light tan precipitate (2.1 g.) recrystd. with Darco from two 100-cc. portions 95% EtOH gave 1.1 g. II, colorless plates, m.

294-5°. II (23.5 g.) dissolved with warming in 250 cc. glacial AcOH, the solution treated dropwise with stirring with 21.4 g. Br in 50 cc. glacial AcOH during 0.5 hr., the mixture heated to boiling, diluted with 250 cc. H₂O, treated with Darco, and cooled, and the resulting colorless solid deposit (25.5 g.) recrystd. twice from 500-cc. portions 50% AcOH gave 16.0 g. 5-bromoacetyl-2-benzimidazolinone (III), colorless crystals, m.

264-6° (decomposition). III (4.7 g.) and 4.4 g. PhCH₂NHMe in 50 cc. EtOH refluxed 2 hrs., the solution diluted with 100 cc. H₂O, stirred, and cooled, the light tan solid deposit (5.1 g.) dissolved in 75 cc. dilute HCl, the solution treated with Darco, basified with excess NaOH, and cooled, the product crystallized twice more from 3% aqueous NaOH, and redissolved in EtOH,

the

alc. solution treated with excess alc. HCl and filtered, the filtrate diluted with Et₂O, and the precipitate recrystd. twice from 75-cc. portions EtOH gave

1.5

g. 5-(N-benzyl-N-methyl-aminoacetyl)-2-benzimidazolinone-2.HCl salt (IV), colorless crystals, m. 252-4° (decomposition). IV (2.0 g.) and 0.3 g. 10% Pd-C in 30 cc. EtOH hydrogenated 18 hrs. at room temperature and 50 lb. pressure, the mixture filtered, the cake dissolved in H₂O and filtered from the catalyst, the filtrate evaporated to dryness, and the solid residue (1.15 g.) dissolved in 100 cc. 50% EtOH, treated with Darco, filtered, diluted with 500 cc. Me₂CO and 400 cc. EtOH, and kept in the cold gave 0.9 g.

5-(N-methylaminoacetyl)-2-benzimidazolinone HCl salt, stout colorless needles, m. above 300°; a 0.6-g. sample dissolved in 10 cc. H₂O, diluted with 150 cc. EtOH and 250 cc. Me₂CO, and cooled gave 0.45 g. pure material, colorless crystalline needles, m. above 300°. IV (1.32 g.) in 30 cc. H₂O hydrogenated 18 hrs. at 50 lb. pressure and room temperature over

0.3

g. 10% Pd-C, the mixture filtered and evaporated to dryness, the colorless

solid

residue (0.85 g.) redissolved in 3 cc. hot H₂O, filtered, and diluted with 75 cc. hot EtOH, and the mixture cooled yielded 0.55 g. 1-(3,4-ureylenephenyl)-2-N-methylaminoethanol HCl salt, colorless crystalline plates, decomposed above 261°; it gave recrystd. in the same manner 0.25 g. pure product, decomposing above 256°. Powdered AlCl₃ (67 g.) added with good stirring during 10 min. to 13 g. 2-benzimidazolone and 23 g. PrCOCl in 76 g. CS₂, the mixture heated 2 hrs. on the steam bath, the dark brown oily mixture poured onto 250 g. cracked ice, treated with 10-15 drops

concentrated

HCl, and filtered, the resulting brown solid filtered off, washed with H₂O, and recrystd. with Darco from 400 cc. 50% EtOH, and the crude yellow product (20 g.) recrystd. twice with Darco from 50% EtOH and then 3 times from 95% EtOH gave 5.2 g. 5-butyryl-2-benzimidazolinone (V), colorless crystals, m. 261-3°. V (22.5 g.) dissolved with warming in 300 cc. glacial AcOH, the solution treated dropwise at 50-60° during 20 min. with 17.6 g. Br in 50 cc. glacial AcOH, the mixture concentrated in vacuo, and

the

light tan crystalline residue recrystd. from a mixture of 350 cc. EtOAc and 150 cc. EtOH gave 20.1 g. α-Br derivative (VI) of V, colorless crystals, m. 233-4° (decomposition); the filtrate concentrated to beginning crystallization

and

recooled gave an addnl. 8.7 g. VI, m. 233-4°; the combined crude material recrystd. gave 22.7 g. pure VI, m. 235-6° (decomposition). VI (2.8 g.) and 3.6 g. Ph₂CHNH₂ in 25 cc. absolute EtOH refluxed 3 hrs., the EtOH distilled off, the light yellow residue triturated with Et₂O, the Et₂O solution shaken with 75 cc. 10% HCl, the resulting oily phase kept several hrs. at room temperature to solidify, and the solid material (3.9 g.) recrystd. twice

from 1:1 EtOH-iso-PrOH gave 2.9 g. 5-[α -(N-benzhydrylamino)butyryl]-2-benzimidazolinone HCl salt (VII), colorless needles, m. 182-4° VII (2.8 g.) and 0.3 g. 10% Pd-C in 30 cc. absolute EtOH hydrogenated 7 hrs. at room temperature and 50 lb. pressure, the mixture diluted with 50 cc. EtOH, heated to boiling, and filtered, the filtrate diluted with 1 l. Me₂CO, and the colorless, crystalline, powdery precipitate (1.1 g.) filtered gave 1-(3,4-ureylenephenyl)-2-aminobutanol HCl salt (VIII), charred without melting between 215 and 250°, and darkened above 200°; the filtrate concentrated gave an addnl. 0.35 g. VIII. The crude VIII (1.1 g.) dissolved in 75 cc. absolute EtOH, the solution diluted with 500 cc. Me₂CO and

250

cc. Et₂O, and the solution cooled deposited 0.90 g. pure VIII. VIII treated with Ac₂O-NaOAc gave 1-(3,4-ureylenephenyl)-2-acetamidobutyl acetate, colorless needles, m. 183-4° (from 50% EtOH). 2-Methyl-5-acetylbenzimidazole (11.5 g.) in 100 cc. glacial AcOH irradiated at 70° with an 100-w. light bulb and treated dropwise with 10.6 g. Br in 25 cc. glacial AcOH during 4 hrs., the excess AcOH distilled off, the tarry residue stirred several hrs. with two 300-cc. portions petr. ether (b. 30-70°), and the resulting white solid recrystd. from 100 cc. 1:1-iso-PrOH gave 6.1 g. 2-methyl-5-(bromoacetyl)benzimidazole (IX) colorless granules, m. approx. 180° on rapid heating; on slow heating it darkened above 250° but did not melt below 300°.

IX (3.8 g.) and 3.6 g. PhCH₂NHMe in 25 cc. EtOH refluxed 1 hr. and concentrated,

the residual red oil triturated with Et₂O, the resulting solid dissolved in alc. HCl and precipitated with Et₂O, this process repeated from

iso-PrOH-Et₂O

yielded 1.0 g. 2-methyl-5-(N-benzyl-N-methylaminoacetyl)benzimidazole (X), m. 238-40° (decomposition). Crude X (1.0 g.) in 30 cc. H₂O hydrogenated 2 hrs. at 40 lb. over 0.2 g. 10% Pd-C, the solution filtered, treated with Darco, and concentrated, the crystalline residue (0.50 g.) recrystd. from 40

cc. 85%

EtOH with Darco, and the colorless solid (0.11 g.) recrystd. from 30 cc.

95% EtOH gave 0.08 g. 2-methyl-5-methylaminoacetylbenzimidazole.2HCl, colorless needles; the original alc. mother liquor (40 cc. 85% EtOH) diluted with 5-6 cc. Et₂O, and the crystalline precipitate (0.2 g.) recrystd. from 50


cc. 95%

EtOH gave 1-(2-methyl-5-benzimidazolyl)-2-methylaminoethanol-2HCl, colorless needles, decomposed above 275°.

IT **853793-95-0**, 2-Benzimidazolinone, 5-[2-(diphenylmethylamino)butyryl]-, hydrochloride **853793-99-4**, 2-Benzimidazolinone, 5-(N-benzylsarcosyl)-, hydrochloride (preparation of)


RN **853793-95-0** HCAPLUS

CN 2-Benzimidazolinone, 5-[2-(diphenylmethylamino)butyryl]-, hydrochloride (5CI) (CA INDEX NAME)



● HCl

RN 853793-99-4 HCAPLUS
 CN 2-Benzimidazolinone, 5-(N-benzylsarcosyl)-, hydrochloride (5CI) (CA INDEX NAME)



● HCl

=> => fil reg

FILE 'REGISTRY' ENTERED AT 11:06:28 ON 22 MAY 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7
 DICTIONARY FILE UPDATES: 19 MAY 2006 HIGHEST RN 885029-44-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Structure search iteration limits have been increased. See HELP SLIMITS for details.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d sca 151

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 9-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro-, monohydrochloride (9CI)
 MF C23 H26 Cl N3 O3 . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):25


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [2-(2-chloro-4-hydroxyphenyl)ethyl][5-oxo-5-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo[4,5,1-ij]quinolin-9-yl)pentyl]-, 1,1-dimethylethyl ester (9CI)
 MF C28 H34 Cl N3 O5



"Free" view of
 dit compounds


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[3-(2-methoxyphenyl)propyl]amino]-1-oxopentyl]-1,3-dimethyl- (9CI)
 MF C24 H31 N3 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-8-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-, monohydrochloride (9CI)
 MF C25 H31 N3 O3 . Cl H



● HCl


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2-Benzimidazolinone, 5-[2-(diphenylmethylamino)butyryl]-, hydrochloride (5CI)
 MF C24 H23 N3 O2 . Cl H



● HCl


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 2H-Benzimidazol-2-one, 5-[6-[[2-(2-chlorophenyl)ethyl]amino]-2-hydroxy-1-oxohexyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI)
 MF C23 H28 Cl N3 O3 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl- (9CI)
 MF C22 H26 Cl N3 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 9-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro- (9CI)
 MF C23 H26 Cl N3 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[1-oxo-5-[(2-phenylethyl)amino]pentyl]-, monohydrochloride (9CI)
 MF C22 H27 N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl- (9CI)
 MF C23 H28 Cl N3 O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl-, monohydrochloride (9CI)
 MF C21 H24 Cl N3 O3 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 6-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-
 1,3-dihydro-1-methyl- (9CI)
 MF C21 H24 Cl N3 O2
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chloro-4-
 hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro-1-methyl- (9CI)
 MF C24 H28 Cl N3 O3
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[1-oxo-5-[[2-

phenylethyl)amino]pentyl]-, monohydrochloride (9CI)
 MF C20 H23 N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]amino]-1-oxopentyl]- (9CI)
 MF C21 H25 N3 O3
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxohexyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI)
 MF C24 H30 Cl N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-


oxopentyl][2-[2-(trifluoromethoxy)phenyl]ethyl]-, 1,1-dimethylethyl ester
(9CI)

MF C28 H34 F3 N3 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[5-[methyl(2-phenylethyl)amino]-1-oxopentyl]- (9CI)
MF C23 H29 N3 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-, monohydrochloride (9CI)
MF C22 H27 N3 O3 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-[(2-ethoxyphenyl)amino]ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl- (9CI)
 MF C24 H32 N4 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[3-(2-methoxyphenyl)propyl]amino]-1-oxopentyl]-1,3-dimethyl-, monohydrochloride (9CI)
 MF C24 H31 N3 O3 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-oxopentyl](2-phenylethyl)-, 1,1-dimethylethyl ester (9CI)
 MF C27 H35 N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dimethyl- (9CI)
 MF C24 H31 N3 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-, monohydrochloride (9CI)
 MF C21 H24 Cl N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl- (9CI)
 MF C21 H24 Cl N3 O2
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-5,6-dihydro-1-methyl-,
 monohydrochloride (9CI)
 MF C25 H30 Cl N3 O2 . Cl H



● HCl


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):25

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2-Benzimidazolinone, 5-(N-benzylsarcosyl)-, hydrochloride (5CI)
 MF C17 H17 N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro-1-methyl-,
 monohydrochloride (9CI)
 MF C24 H28 Cl N3 O3 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [2-(2-chloro-4-hydroxyphenyl)ethyl][5-oxo-5-(1,2,5,6-tetrahydro-1-methyl-2-oxo-4H-imidazo[4,5,1-ij]quinolin-8-yl)pentyl]-, 1,1-dimethylethyl ester (9CI)
 MF C29 H36 Cl N3 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[methyl(2-phenylethyl)amino]-1-oxopentyl]- (9CI)
 MF C21 H25 N3 O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dimethyl-, monohydrochloride (9CI)
 MF C23 H29 N3 O3 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxohexyl]-1,3-dihydro-1,3-dimethyl- (9CI)
 MF C24 H30 Cl N3 O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 6-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl-, monohydrochloride (9CI)
 MF C21 H24 Cl N3 O3 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 6-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl- (9CI)
 MF C21 H24 Cl N3 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro- (9CI)
 MF C20 H22 Cl N3 O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]amino]-1-oxopentyl]-, monohydrochloride (9CI)
 MF C21 H25 N3 O3 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[1-oxo-5-[(2-phenylethyl)amino]pentyl]- (9CI)
 MF C20 H23 N3 O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl-, monohydrochloride (9CI)
 MF C21 H24 Cl N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-oxopentyl][2-(2-ethoxyphenoxy)ethyl]-, 1,1-dimethylethyl ester (9CI)
 MF C29 H39 N3 O6




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-5,6-dihydro- (9CI)
 MF C24 H28 Cl N3 O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[5-[methyl(2-phenylethyl)amino]-1-oxopentyl]-, monohydrochloride (9CI)
 MF C23 H29 N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro- (9CI)
 MF C23 H26 Cl N3 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-ethoxyphenoxy)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI)
 MF C24 H31 N3 O4 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-oxopentyl][2-(2-methoxyphenyl)ethyl]-, 1,1-dimethylethyl ester (9CI)
 MF C28 H37 N3 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-8-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]- (9CI)
 MF C25 H31 N3 O3
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI)
 MF C23 H28 Cl N3 O2 . Cl H



● HCl


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-8-[5-[[2-(2-

methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-1-methyl- (9CI)
 MF C26 H33 N3 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-8-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-1-methyl-, monohydrochloride (9CI)
 MF C26 H33 N3 O3 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[2-[(diphenylmethyl)amino]-1-oxobutyl]-1,3-dihydro- (9CI)
 MF C24 H23 N3 O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-5,6-dihydro-, monohydrochloride (9CI)
 MF C23 H26 Cl N3 O3 . Cl H



● HCl


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [2-(2-chloro-4-hydroxyphenyl)ethyl][5-oxo-5-(1,2,5,6-tetrahydro-2-oxo-4H-imidazo[4,5,1-ij]quinolin-8-yl)pentyl]-, 1,1-dimethylethyl ester (9CI)
 MF C28 H34 Cl N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):25

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[6-[[2-(2-chlorophenyl)ethyl]amino]-2-hydroxy-1-oxohexyl]-1,3-dihydro-1,3-dimethyl- (9CI)
 MF C23 H28 Cl N3 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-5,6-dihydro-, monohydrochloride (9CI)
 MF C24 H28 Cl N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-ethoxyphenoxy)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl- (9CI)
 MF C24 H31 N3 O4
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, monohydrochloride (9CI)
 MF C22 H26 Cl N3 O3 . Cl H



● HCl


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[[2-(2-chloro-4-hydroxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dihydro-1-methyl- (9CI)
 MF C21 H24 Cl N3 O3
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[1-oxo-5-[[2-(2-(trifluoromethoxy)phenyl)ethyl]amino]pentyl]- (9CI)

MF C23 H26 F3 N3 O3
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2H-Benzimidazol-2-one, 5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-
1,3-dihydro-, monohydrochloride (9CI)
MF C20 H22 Cl N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 8-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-5,6-dihydro-1-methyl- (9CI)
MF C25 H30 Cl N3 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 6-[5-[[2-(2-chlorophenyl)ethyl]amino]-1-oxopentyl]-
 1,3-dihydro-1-methyl-, monohydrochloride (9CI)
 MF C21 H24 Cl N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-oxopentyl][2-[(2-ethoxyphenyl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI)
 MF C29 H40 N4 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-(2-chlorophenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dihydro- (9CI)
 MF C21 H24 Cl N3 O2
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]-1,3-dimethyl-,
 monohydrochloride (9CI)
 MF C24 H31 N3 O3 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]amino]-1-oxopentyl]-1,3-dimethyl- (9CI)
 MF C23 H29 N3 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 5-[5-[[2-[(2-ethoxyphenyl)amino]ethyl]amino]-1-oxopentyl]-1,3-dihydro-1,3-dimethyl-, dihydrochloride (9CI)
 MF C24 H32 N4 O3 . 2 Cl H




● 2 HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Carbamic acid, [2-(2-chlorophenyl)ethyl][5-(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI)
 MF C27 H34 Cl N3 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[[2-(2-methoxyphenyl)ethyl]methylamino]-1-oxopentyl]- (9CI)
 MF C22 H27 N3 O3
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[5-[methyl(2-phenylethyl)amino]-1-oxopentyl]-, monohydrochloride (9CI)
 MF C21 H25 N3 O2 . Cl H




● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[1-oxo-5-[(2-phenylethyl)amino]pentyl]- (9CI)
 MF C22 H27 N3 O2
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-1,3-dimethyl-5-[1-oxo-5-[[2-[2-(trifluoromethoxy)phenyl]ethyl]amino]pentyl]-, monohydrochloride (9CI)
 MF C23 H26 F3 N3 O3 . Cl H



● HCl

L51 71 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[[methyl(phenylmethyl)amino]acetyl]-

(9CI)
 MF C17 H17 N3 O2
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 10:43:29 ON 22 MAY 2006)
 DEL HIS

FILE 'HCAPLUS' ENTERED AT 10:44:43 ON 22 MAY 2006

```

SET COST OFF
L1      1 S (US20060063769 OR US20050197362)/PN OR (US2004-500217# OR US2
      E ISHIHARA/AU
      E ISHIHARA Y/AU
L2      94 S E3
      E ISHIHARA YU/AU
L3      84 S E3,E6
      E YUJI/AU
L4      6 S E3
      E ISHICHI/AU
L5      19 S E4,E8
      E DOI/AU
L6      1 S E3
      E DOI T/AU
L7      366 S E3,E4,E30
      E TAKAYUKI/AU
L8      2 S E3
      E NAGABUKURO/AU
L9      17 S E6,E7
      E HIROSHI/AU
L10     14 S E3
      E HIROSHI N/AU
L11     4 S E11
      E KANXAKI/AU
      E KANZAKI/AU
L12     1 S E3
      E KANZAKI N/AU
L13     85 S E3,E4,E7
      E NAOYUKI/AU
      E IKEUCHI/AU
      E IKEUCHI M/AU
L14     35 S E3
      E IKEUCHI MO/AU
L15     19 S E5,E9

```

L16 E MOTOKI/AU
 1 S E88
 E ISHIHARA N/AU
 L17 14 S E6
 E YUJI N/AU
 L18 17 S E6
 E ISHICHI N/AU
 E YUJI N/AU
 L19 17 S E6
 E DOI N/AU
 L20 13 S E6
 E TAKAYUKI N/AU
 E NAGABUKURO N/AU
 E HIROSHI N/AU
 L21 4 S E11
 E KANZAKI N/AU
 L22 4 S E4
 E NAOYUKI N/AU
 E IKEUCHI N/AU
 L23 7 S E4
 E MOTOKI N/AU
 L24 1 S E4
 L25 14848 S TAKEDA?/PA,CS
 L26 1 S L1 AND L2-L24
 L27 1 S L1 AND L25
 L28 1 S L1,L26,L27

FILE 'REGISTRY' ENTERED AT 10:51:33 ON 22 MAY 2006

FILE 'HCAPLUS' ENTERED AT 10:51:40 ON 22 MAY 2006

L29 TRA L28 1- RN : 641 TERMS

FILE 'REGISTRY' ENTERED AT 10:51:41 ON 22 MAY 2006

L30 641 SEA L29
 L31 34 S L30 AND NCNC2-C6/ES AND 46.150.18/RID AND 3/NR
 L32 12 S L31 AND 3/N AND 2/O AND CL/ELS
 L33 1 S L32 AND 1/NC
 L34 5 S L31 AND 22/C
 L35 1 S L34 AND C22H26CLN3O2
 L36 1 S 773845-97-9
 L37 1 S 773845-97-9/CRN
 L38 2 S L36,L37

FILE 'HCAOLD' ENTERED AT 10:54:55 ON 22 MAY 2006

L39 0 S L38

FILE 'HCAPLUS' ENTERED AT 10:54:56 ON 22 MAY 2006

L40 2 S L38
 L41 2 S L40 AND L1-L28

FILE 'USPATFULL, USPAT2' ENTERED AT 10:55:16 ON 22 MAY 2006

L42 2 S L38

FILE 'REGISTRY' ENTERED AT 10:55:35 ON 22 MAY 2006

FILE 'USPATFULL, USPAT2' ENTERED AT 10:55:42 ON 22 MAY 2006

FILE 'HCAPLUS' ENTERED AT 10:55:52 ON 22 MAY 2006

FILE 'REGISTRY' ENTERED AT 10:56:26 ON 22 MAY 2006

L43 STR
L44 2 S L43
L45 73 S L43 FUL
SAV L45 TEMP SHIAO500/A
L46 71 S L45 NOT L38
L47 29 S L46 NOT L30
L48 22 S L47 AND NCNC2-C6/ES
L49 7 S L47 NOT L48
L50 42 S L46 AND L30
L51 71 S L46-L50
SAV TEMP L51 SHIAO500A/A

FILE 'HCAOLD' ENTERED AT 11:03:30 ON 22 MAY 2006
L52 0 S L51

FILE 'HCAPLUS' ENTERED AT 11:03:33 ON 22 MAY 2006
L53 3 S L51
L54 2 S L53 AND L1-L25
L55 1 S L53 NOT L54

FILE 'USPATFULL, USPAT2' ENTERED AT 11:04:13 ON 22 MAY 2006
L56 2 S L51

FILE 'REGISTRY' ENTERED AT 11:04:23 ON 22 MAY 2006

FILE 'USPATFULL, USPAT2' ENTERED AT 11:04:31 ON 22 MAY 2006

FILE 'HCAPLUS' ENTERED AT 11:04:44 ON 22 MAY 2006

FILE 'REGISTRY' ENTERED AT 11:06:28 ON 22 MAY 2006

=>